Brokerages Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Target Price at $37.60

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $37.80.

A number of research firms have recently issued reports on GMAB. Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday. Truist Financial increased their target price on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 8th. HC Wainwright reiterated a “buy” rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Finally, Sanford C. Bernstein lowered Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $21.46 on Tuesday. The stock has a fifty day moving average price of $21.04 and a two-hundred day moving average price of $20.75. The firm has a market cap of $13.77 billion, a P/E ratio of 12.19, a PEG ratio of 6.51 and a beta of 0.94. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $28.56.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. The firm had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. On average, research analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently bought and sold shares of the business. EverSource Wealth Advisors LLC grew its position in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares during the last quarter. Headlands Technologies LLC grew its position in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after purchasing an additional 1,464 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after purchasing an additional 1,070 shares during the last quarter. Barclays PLC grew its position in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Genmab A/S in the fourth quarter valued at about $60,000. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.